Matrix-Directed Therapy In Older Adolescents And Adults With Osteogenesis Imperfecta – The “MOI-A” Study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515516-50-00

Acronym

MOI-A

Enrollment

Registered

2025-03-13

Start date

2025-09-18

Completion date

Unknown

Last updated

2025-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteogenesis Imperfecta

Brief summary

Percentage change in CTX from baseline to week 24

Detailed description

Percentage change in CTX from baseline to week 8, Percentage change in TGFβ & P1NP from baseline to week 8 and w24, Change in DXA LSaBMD from baseline to w24, Change in radial and tibial total vBMD by HRpQCT from baseline to w24, Change in Timed Up and Go test from baseline to w24, Change in QoL using OI-QOL & EQ-5D-5L-VAS from baseline to w24

Interventions

DRUGLOSARTAN

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage change in CTX from baseline to week 24	—

Secondary

Measure	Time frame
Percentage change in CTX from baseline to week 8, Percentage change in TGFβ & P1NP from baseline to week 8 and w24, Change in DXA LSaBMD from baseline to w24, Change in radial and tibial total vBMD by HRpQCT from baseline to w24, Change in Timed Up and Go test from baseline to w24, Change in QoL using OI-QOL & EQ-5D-5L-VAS from baseline to w24	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026